News
TriMaster study shows precision medicine in diabetes is possible
The novel TriMaster trial of three type 2 diabetes drug classes shows different ones work better for different patients.
News
Age, C-reactive protein predict COVID-19 death in diabetes
“This means we can easily identify patients early on in their hospital stay who will likely require more aggressive interventions to try and...
News
EASD: Precision in diabetes management and impact of COVID-19
The European Association for the Study of Diabetes annual meeting will feature precision medicine sessions, a consensus statement on type 1...
News
Type 2 diabetes ‘remission’ is a reality, say major organizations
A new consensus statement by four major diabetes organizations aims to standardize the definition and assessment of type 2 diabetes ‘remission.’...
News
Emerging data point to underlying autoimmunity in ME/CFS
Findings suggest that potential treatments targeting autoantibodies may alleviate symptoms.
News
New recommendations address ME/CFS diagnosis and management
Document is based on expert clinician experience in illness that has long been overlooked and inappropriately managed.
News
FDA approves rapid-acting insulin, Lyumjev, for pump use
Approved for diabetes treatment last year, it’s the second ultra-rapid-acting insulin approved for use in insulin delivery devices.
News
Half abandon metformin within a year of diabetes diagnosis
Multiple factors are blamed for the drop-off, while improved communication, follow-up, and medication adjustment are advised as remedies.
News
FDA clears app for FreeStyle Libre 2 glucose monitor
System includes optional alarms; app allows for remote monitoring.
News
‘Shocking’ early complications from teen-onset type 2 diabetes
Almost two-thirds of study participants had at least one diabetes complication in young adulthood, around 15 years after diagnosis. A handful died...
News
FDA approves first interchangeable biosimilar insulin
The approval will allow Semglee to function like a generic drug in the market and may reduce insulin costs.
News
FDA okays extended-release exenatide for children with T2D
It’s the second GLP-1 receptor agonist approved for youth with type 2 diabetes, and the first once-weekly.
